Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence

Self-amplified activatable nanophotosensitizers for HIF-1α inhibition-enhanced photodynamic therapy

“…25 However, most of these inhibitors are small molecules that have undesirable biodistribution and poor tumor targeting capability. 26 Although loading them into nanocarriers may increase their tumor accumulation, the issue of burst release during circulation induces inevitable side effect, which endows the development of novel nanosystems for HIF-1α inhibitors delivery with great value. 27,28…”